

CODEBASE VENTURES INC.

UK: +44 (0)207 989 0813 NA: +1 646 896 3065 AU +61 2 9280 0700 action@proactiveinvestors.com

08:40 20 May 2020

Codebase Ventures updates on strategy to develop transdermal delivery system for hydroxychloroquine

Codebase Ventures Inc (CSE:CODE) (OTCQB:BKLLF) on Wednesday provided an update on its strategy toward the development of a transdermal delivery system for hydroxychloroquine as a potential treatment for patients with coronavirus (COVID-19).

The company noted that the US National Institutes of Health (NIH) have launched a Phase IIb double-blind clinical trial to study hydroxychloroquine and azithromycin treatments in patients with COVID-19.

The main objective of the study is to determine whether the drug combo can prevent hospitalization and death. Additionally, investigators will evaluate the safety and tolerability of the experimental treatment for people infected with SARS-CoV-2, the virus that causes the COVID-19 disease.

READ: Codebase Ventures says World High Life subsidiary has advanced product development cycle to meet rising demand for CBD in UK

Codebase also pointed out that US President Donald Trump has announced that he himself is taking hydroxychloroquine as a precaution.

The company recently acquired 49% of a private pharmaceutical company which has recently filed for two US provisional patents for transdermal delivery and oral mucosal delivery of chloroquine (CQ) and hydroxychloroquine.

The private pharmaceutical company has a lab services agreement with Reformulation Research Laboratories Inc (RRL), which has led to the development of the patent applications and the underlying technology.

Codebase has stressed that it is not making any express or implied claims that chloroquine and hydroxychloroquine have any effect in the prevention or treatment of COVID-19 at this time.

Developing a transdermal or oral mucosal delivery of these drugs could help patients suffering from other diseases and viruses, the company said, noting that such technologies could lead to lower dosages and common side effects felt by patients for their on-label treatment for lupus, rheumatoid arthritis and malaria.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham



Share Information

Code:		CODE
Listing:		CSE
52 week	High	Low
	0.35	0.04

Sector: Financial Services
Website: www.codebase.ventures

Company Synopsis:

Codebase Ventures Inc. is a small, handson team of financial and technology experts who invest early in great ideas. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders.

action@proactiveinvestors.com



Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CODEBASE VENTURES INC. named herein, including the promotion by the Company of CODEBASE VENTURES INC. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).